Health Care & Life Sciences » Biotechnology | IBEX Technologies Inc.

IBEX Technologies Inc. | Cash Flow

Fiscal year is August-July. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
40.40
480.70
209.60
100.60
2,981.80
95.20
Depreciation, Depletion & Amortization
344.70
406.70
351.50
335.30
273.60
284.40
Other Funds
80.30
135.40
-
-
16.50
94.90
Funds from Operations
52.50
61.30
561.10
429.30
805.80
345.30
Changes in Working Capital
371.40
113.00
108.40
494.10
269.10
129.30
Net Operating Cash Flow
318.90
174.40
452.70
923.50
1,074.90
216
Capital Expenditures
390.00
53.60
14.30
61.60
921.10
Sale of Fixed Assets & Businesses
-
21.50
-
-
-
Purchase/Sale of Investments
1,000.00
-
-
-
-
Net Investing Cash Flow
1,374.10
32.10
14.30
61.60
921.10
Issuance/Reduction of Debt, Net
957.60
35.00
40.50
47.00
48.80
Net Financing Cash Flow
957.60
35.00
40.50
47.00
48.80
Net Change in Cash
97.60
107.30
397.90
814.80
105.00
Free Cash Flow
71.10
120.80
438.50
861.80
194.20
Deferred Taxes & Investment Tax Credit
357.30
-
-
6.50
2,466.20
61.20
Net Assets from Acquisitions
1,984.10
-
-
-
-

About IBEX Technologies

View Profile
Address
5485, rue Pare
Montréal Québec H4P 1P7
Canada
Employees -
Website http://www.ibex.ca
Updated 07/08/2019
IBEX Technologies, Inc. manufactures and markets diagnostic products. It manufactures and markets enzymes for biomedical use. The enzymes are used for manufacturers of medical devices, quality control labs and academic research institutions.